基因治療市場機會、成長要素、產業趨勢分析及2026-2035年預測。

全球基因治療市場預計到 2025 年價值 33 億美元，預計到 2035 年將達到 336 億美元，年複合成長率為 26.2%。

基因遞送技術的持續進步、基因載體的不斷開發、基因治療研究投入的增加、癌症和其他目標疾病發病率的上升、細胞和基因治療生產服務的日益普及，以及越來越多的產品獲得批准並實現商業化，共同推動了基因治療市場的強勁成長。此外，人們對能夠治療選擇有限的疾病的創新療法的需求不斷成長，也促進了基因治療市場的發展。精準醫療意識的提高、基因檢測技術的進步以及生產能力的提升，進一步推動了基因療法在整個醫療保健系統中的應用。基因治療是指透過修改、替換或導入患者細胞內的遺傳物質來預防、控制或治療疾病。這項技術可望透過解決疾病的根本遺傳原因，而非僅僅控制症狀，以實現長期的治療效果。隨著研究活動的持續拓展和商業化的加​​速推進，預計該市場將在預測期內保持持續成長。

遺傳性疾病和罕見疾病負擔的日益加重，持續為基因治療市場創造巨大的機會。對於許多遺傳性疾病而言，以往的治療選擇十分有限，這使得基因療法對於尋求持久療效的醫療專業人員和患者而言，成為越來越有吸引力的解決方案。在許多情況下，單次治療即可帶來長期的臨床效益，從而減少持續用藥和疾病管理的需求。疾病認知度的提高、基因篩檢的普及以及診斷技術的進步，正在擴大基因治療和臨床研究計畫的適用人群。同時，基因遞送平台的不斷進步，正在提升治療的精準度、生產效率和整體療效，進一步推動市場成長。

預計到2025年，體內基因治療市場規模將達27億美元。這個領域保持主導地位的原因在於，體內治療能夠將治療性基因直接遞送至患者體內，從而透過系統性方法治療多個器官和組織。這種能力對於影響多個身體系統的疾病尤其重要。遞送技術的持續創新正在提高基因物質遞送的準確性、效率和安全性，從而改善治療效果，並加速體內基因療法在臨床應用中的普及。

預計到2025年，腫瘤治療領域將佔據46.5%的市場佔有率，並在2026年至2035年間以24.2%的複合年成長率成長。該領域持續引領市場，因為基因療法能夠將治療基因直接靶向遞送至癌細胞，同時最大限度地減少對周圍健康組織的影響。這種精準的治療方法有助於改善治療效果，並減輕傳統療法常見的副作用。此外，基因療法正被評估與現有治療策略合併應用，以期改善整體臨床療效。全球癌症發生率的不斷上升也持續推動對創新基因治療解決方案的強勁需求。

預計到2025年，北美基因治療市佔率將達到62.5%。這一成長得益於有利的法律規範、大量的公共和私人投資、先進的醫療基礎設施以及高度發展的研究環境。該地區的優勢還在於其生技公司、研究機構和醫療機構的集中，這些機構不斷加速基因治療產業的創新和商業化進程。對科學研究、生產能力和臨床開發的持續投入進一步鞏固了北美的領先地位，並支持其市場的長期擴張。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 促進因素
    • 基因編輯技術的進步
    • 罕見遺傳疾病和遺傳病患疾病率不斷上升
    • 增加投資和合作
    • 人們對基因診斷技術的認知不斷提高，以及基因診斷技術的進步
  • 產業潛在風險與挑戰
    • 高昂的研發和製造成本
    • 基因治療給藥的複雜性與潛在副作用
  • 市場機遇
    • 開發個人化和精準基因療法
    • 在醫療基礎設施正在發展的新興市場拓展業務。
• 成長潛力分析
• 監理情勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
• 技術與創新展望
  • 最新科技趨勢
  • 新興技術
• 價格分析
  • 對過去價格趨勢的分析
  • 價格分析：依療法類型
• 波特的分析
• PESTLE分析
• 投資與資金籌措分析
  • 全球基因治療投資趨勢（2022-2026）
  • 政府、美國國立衛生研究院和津貼資金籌措情況
• 已獲批准且市售的基因治療產品
• 研發管線和臨床試驗趨勢
• 未來市場趨勢
• 人工智慧和生成式人工智慧對市場的影響

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依治療方法分類，2022-2035年

• 體內基因治療
• 體外基因治療

第6章 市場估算與預測：以交付方式分類，2022-2035年

• 病毒載體
  • 腺結合病毒載體
  • 慢病毒載體
  • 逆轉錄病毒和γ逆轉錄病毒
  • 其他病毒載體
• 非病毒載體

第7章 市場估計與預測：依適應症分類，2022-2035年

• 腫瘤學
• 罕見疾病和遺傳疾病
• 血液學
• 眼科
• 其他改編

第8章 市場估算與預測：依最終用途分類，2022-2035年

• 醫院
• 專科診所和基因治療中心
• 學術和研究機構
• 其他最終用戶

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • UAE

第10章：公司簡介

• Amgen
• Bayer
• BioMarin
• bluebird bio
• Bristol Myers Squibb
• CRISPR Therapeutics
• Ferring Pharmaceuticals
• Gilead Sciences
• Krystal Biotech
• Novartis
• Orchard Therapeutics
• Pfizer
• Sarepta Therapeutics
• Spark Therapeutics（Roche）
• UniQure
• Vertex Pharmaceuticals

The Global Gene Therapy Market was valued at USD 3.3 billion in 2025 and is estimated to grow at a CAGR of 26.2% to reach USD 33.6 billion by 2035.

Strong market growth is supported by continuous advancements in gene delivery technologies, expanding development of gene vectors, rising investments in gene therapy research, increasing incidence of cancer and other target diseases, broader availability of cell and gene therapy manufacturing services, and the growing number of product approvals and commercial launches. The gene therapy market is also benefiting from the increasing demand for innovative treatment options capable of addressing diseases with limited therapeutic alternatives. Growing awareness of precision medicine, improvements in genetic testing, and advances in manufacturing capabilities are encouraging wider adoption of gene-based therapies across healthcare systems. Gene therapy involves modifying, replacing, or introducing genetic material within a patient's cells to prevent, manage, or treat disease. The technology offers the potential for long-lasting therapeutic outcomes by addressing the underlying genetic cause of disease rather than simply controlling symptoms. As research activities continue to expand and commercialization accelerates, the market is expected to experience sustained growth throughout the forecast period.

The rising burden of genetic and rare diseases continues to create significant opportunities for the gene therapy market. Many inherited disorders have historically offered limited treatment options, making gene therapy an increasingly attractive solution for healthcare providers and patients seeking durable therapeutic outcomes. In many cases, a single treatment has the potential to deliver long-term clinical benefits, reducing the need for continuous medication and ongoing disease management. Improvements in disease awareness, genetic screening, and diagnostic technologies are identifying a larger patient population eligible for gene therapy treatments and clinical research programs. At the same time, ongoing progress in gene delivery platforms is improving treatment precision, manufacturing efficiency, and overall therapeutic performance, further supporting market expansion.

The in vivo gene therapy segment generated USD 2.7 billion in 2025. This segment maintains its leadership because in vivo therapies allow therapeutic genes to be delivered directly into the patient's body, enabling treatment across multiple organs and tissues through a systemic approach. Such capabilities are particularly valuable for diseases affecting several body systems. Continuous innovation in delivery technologies has also enhanced the accuracy, efficiency, and safety of genetic material delivery, contributing to improved therapeutic outcomes and accelerating adoption of in vivo gene therapy across clinical applications.

The oncology segment accounted for 46.5% share in 2025 and is anticipated to grow at a CAGR of 24.2% between 2026 and 2035. The segment continues to lead the market because gene therapy enables targeted delivery of therapeutic genes directly to cancer cells while minimizing the impact on surrounding healthy tissues. This precision-based treatment approach helps improve therapeutic effectiveness while reducing unwanted side effects commonly associated with conventional treatment methods. In addition, gene therapy is increasingly being evaluated alongside existing treatment strategies to improve overall clinical outcomes. The growing global prevalence of cancer continues to support strong demand for innovative gene-based therapeutic solutions.

North America Gene Therapy Market held a 62.5% share in 2025. Regional growth is supported by a favorable regulatory framework, substantial public and private investment, advanced healthcare infrastructure, and a highly developed research environment. The region also benefits from a strong concentration of biotechnology companies, research organizations, and healthcare institutions that continue to accelerate innovation and commercialization within the gene therapy industry. Ongoing investments in scientific research, manufacturing capabilities, and clinical development continue to reinforce North America's leadership position and support long-term market expansion.

Leading participants operating in the global gene therapy market include Novartis, BioMarin, Vertex Pharmaceuticals, Orchard Therapeutics, Pfizer, UniQure, Amgen, Bayer, Ferring Pharmaceuticals, Gilead Sciences, CRISPR Therapeutics, Bristol Myers Squibb, Krystal Biotech, bluebird bio, Sarepta Therapeutics, and Spark Therapeutics (Roche). Companies operating in the gene therapy market are strengthening their competitive position through continuous investment in research and development, expansion of manufacturing capacity, and advancement of proprietary gene delivery technologies. Strategic collaborations with biotechnology firms, research institutions, and contract manufacturing organizations are helping accelerate product development and commercialization. Many companies are broadening their clinical pipelines by targeting multiple therapeutic areas while enhancing manufacturing scalability and process efficiency to support growing commercial demand. Organizations are also pursuing regulatory approvals across additional markets, expanding geographic presence, and investing in advanced production facilities to improve supply capabilities.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Market estimates & forecasts parameters
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Therapy type trends
  • 2.2.3 Vector type trends
  • 2.2.4 Indication trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancements in gene editing technologies
    • 3.2.1.2 Increasing prevalence of rare genetic and inherited diseases
    • 3.2.1.3 Rising investments and collaborations
    • 3.2.1.4 Growing awareness and improved genetic diagnostics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development and manufacturing costs
    • 3.2.2.2 Complexity of gene therapy delivery and potential side effects
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of personalized and precision gene therapies
    • 3.2.3.2 Expansion in emerging markets with growing healthcare infrastructure
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis (Driven by Primary Research)
  • 3.6.1 Historical price trend analysis
  • 3.6.2 Pricing analysis, by therapy type
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis
• 3.9 Investment & funding analysis
  • 3.9.1 Global gene therapy investment trends (2022–2026)
  • 3.9.2 Government, NIH & grant funding landscape
• 3.10 Approved & commercialized gene therapy products
• 3.11 Pipeline and clinical trial landscape
• 3.12 Future market trends
• 3.13 Impact of AI & Generative AI on the market

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Therapy Type, 2022 – 2035 ($ Mn)

• 5.1 Key trends
• 5.2 In vivo gene therapy
• 5.3 Ex vivo gene therapy

Chapter 6 Market Estimates and Forecast, By Delivery Method, 2022 – 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Viral vectors
  • 6.2.1 Adeno-associated virus vectors
  • 6.2.2 Lentiviral vectors
  • 6.2.3 Retrovirus & γ-Retrovirus
  • 6.2.4 Other viral vectors
• 6.3 Non-viral vectors

Chapter 7 Market Estimates and Forecast, By Indication, 2022 – 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Oncology
• 7.3 Rare and genetic disorders
• 7.4 Hematology
• 7.5 Ophthalmology
• 7.6 Other indications

Chapter 8 Market Estimates and Forecast, By End Use, 2022 – 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics and gene therapy centers
• 8.4 Academic and research institutions
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 – 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Amgen
• 10.2 Bayer
• 10.3 BioMarin
• 10.4 bluebird bio
• 10.5 Bristol Myers Squibb
• 10.6 CRISPR Therapeutics
• 10.7 Ferring Pharmaceuticals
• 10.8 Gilead Sciences
• 10.9 Krystal Biotech
• 10.10 Novartis
• 10.11 Orchard Therapeutics
• 10.12 Pfizer
• 10.13 Sarepta Therapeutics
• 10.14 Spark Therapeutics (Roche)
• 10.15 UniQure
• 10.16 Vertex Pharmaceuticals